Written Question·Department of Health and Social Care·UIN 16571

Fezolinetant

Tabled: 7 July 2026

Answered: 15 July 2026

Question

Dr Luke Evans

To ask the Secretary of State for Health and Social Care, what assessment he has made of levels of regional variation in access to fezolinetant across England.

Answer

Preet Kaur Gill

The National Institute for Health and Care Excellence (NICE) published guidance on 31 March 2026 recommending fezolinetant as an option for treating moderate to severe menopause-related hot flushes and night sweats when hormone replacement therapy is unsu...

ⓘ

This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 16571) →